Alpback Workshop

MENU menu

9th Alpbach Workshop on
Affinity Proteomics
March 11-13 2019

CONFIRMED SPEAKERS AND CHAIRS

MATHIAS UHLEN

Mathias Uhlen’s research is focused on protein science, antibody engineering and precision medicine and ranges from basic research in human and microbial biology to more applied research, including clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. It has resulted in more than 550 publications with a current h-index of 111. His group was the first to describe a number of innovations including: engineered protein A and protein G for purification of antibodies, affinity tags for purification of recombinant fusion proteins, solid phase techniques for DNA handling using the biotin-streptavidin system, Pyrosequencing leading to the first next generation DNA sequencing instrument (454/Roche), and Affibodies, protein binders aimed at therapeutic applications. Since 2003, he has led an international effort to systematically map the human proteome with antibodies and to create an open source knowledge-based resource called the Human Protein Atlas (www.proteinatlas.org).

Mathias Uhlen

HIDDE PLOEGH

Hidde Ploegh performed  his Ph.D. work with Jack Strominger at Harvard University. After positions in Germany and the Netherlands, he held the Mallinckrodt Professorship in Immunopathology at Harvard Medical School, and joined the faculty of MIT and the Program in Cellular and Molecular Medicine at the Boston Children’s Hospital.

 

Dr. Ploegh has driven the analysis of antigen presentation. His lab was the first to report the cloning of cDNA for a human MHC product and pioneered the use of HLA transgenic mice to examine human MHC products as restriction elements. He established the importance of the intersection between the endocytic pathway and the intracellular trafficking routes of Class II MHC products as key to antigen presentation.  His recent work on bacterial sortases provided tools for the generation of previously genetically impossible protein transformations, leading to improved cytokines and improved single domain camelid antibodies. He is a correspondent of the Royal Dutch Academy of Sciences, a member of EMBO and NAS, and a fellow of AAAS.

Ulf Landegren

ULF LANDEGREN

Ulf Landegren MD PhD is Professor of Molecular Medicine in Uppsala University, where his group develops molecular tools for precision medicine at the levels of nucleic acids and proteins. He is a member of EMBO, the Royal Swedish Academy of Sciences and the Scientific Advisory Committee for European Academies, as well as several industrial scientific advisory boards. He has authored 200+ peer-reviewed publications, and is the inventor of 44 patents. His lab has developed technologies such as padlock probes and proximity ligation and extension reactions. The technologies have been licensed to 15 international biotech and diagnostic companies, and nine companies have their origin in his lab.

Ulf Landegren

STEFAN DÜBEL

Stefan Dübel co-pioneered in-vitro antibody selection technologies, resulting in several key inventions including antibody phage display (USPat. 5849500) and human antibody libraries with randomized CDRs (USPat. 5840479). Other technologies developed in his lab, e.g. Hyperphage technology, are also broadly used by labs all over the world. His lab further contributed to multiple topics related to antibody engineering, fusion proteins for cancer therapy, and high throughput human antibody generation. Recently, his lab introduced protein knockdown mice based on intrabody technology. He has published >200 scientific papers and is Editor of the four volume reference "Handbook of Therapeutic Antibodies". He is Full Professor of Biotechnology and Director of the respective department at the Technische Universität Braunschweig, Germany, and co-founder of the human antibody company YUMAB.

Stefan Dubel

JÖRG HOHEISEL

Jörg Hoheisel heads the Division of Functional Genome Analysis at the Deutsches Krebsforschungszentrum (DKFZ; German Cancer Research Center) in Heidelberg, Germany. His research objective is the development and immediate application of technologies for an assessment and description of the realisation and regulation of cellular function from genetic information. He currently has a particular focus on the analysis of protein variations and interactions by means of affinity proteomics. Another line of work is Synthetic Biology for the in vitro production of functional biomolecules and the establishment of artificial molecular systems. Earlier achievements were his involvement in the sequencing of the yeast genome as a coordinator and developments in the area of microarray technology. Jörg has also co-founded five companies; another four were formed independently by former group members.

Jog Hoheisel

ANDREAS PLÜCKTHUN

Andreas Plückthun is Professor of Biochemistry at the University of Zürich. His research is centered on protein engineering. His contributions have included many aspects of structure-based antibody engineering, expression technology, design of synthetic antibody libraries, the development of ribosome display as an in vitro protein evolution technology, development of new scaffolds (the DARPin technology), and the directed evolution of G-protein coupled receptors towards high stability. His lab is combining computer-aided protein design, directed evolution, biophysics and cell biology. He is a member of the German Academy of Science (Leopoldina) and EMBO. His work has been published in over 400 papers, which have been cited over 33,000 times (h-index 106). He has receive numerous prizes including the 2016 Christian Anfinsen Award for "pioneering contributions to protein engineering". He co-founded MorphoSys AG (1992), Molecular Partners AG in Zurich (2004) and G7 Therapeutics in Zurich (2014). 

MICHAEL WEINER

Michael Weiner, Ph.D. has successfully delivered several well-known products to the research marketplace, including QuikChange Mutagenesis (Stratagene Cloning Systems, over 100,000 citations in the literature), Luminex bead-based SNP genotyping, Next Generation DNA sequencing (454 Life Sciences, >6,000 citations), and microfluidic-based digital PCR (RainDance Technologies).  He is currently the VP of Molecular Sciences at Abcam where his primary responsibilities are to develop and oversee advanced methods for the discovery and production of recombinant antibodies.  His recent research has been focused on a means to identify de novo and produce high affinity IgG molecules within 2 weeks upon receipt of an antigen.

Michael Weiner

FRIDTJOF LUND-JOHANSEN

Fridtjof Lund-Johansen leads a proteomics research group at the Oslo University Hospital in Norway. The goal of his research is to develop a unified platform for antibody-and mass spectrometry (MS)-based proteomics. His technology is called Microsphere Affinity Proteomics (MAP) and involves labelling and extensive fractionation of sample proteins followed by parallel readout with MS- and microsphere-based antibody arrays.  With MAP, the targets of thousands of antibodies are resolved as discrete reactivity peaks across the fractions, and the MS results are used to identify peaks that correspond to specific binding. By allowing parallel use of thousands of antibodies, MAP brings a true proteomics perspective into the field of antibody-based detection.

SAREL FLEISHMAN

Sarel Fleishman is an assistant professor at the Weizmann Institute of Science, where his team develops methods for computational design of proteins, including antibodies, vaccine immunogens, and therapeutic enzymes. The team recently developed a fully automated method, called PROSS, for dramatically improving the stability and expressibility of recalcitrant proteins and methods for improving affinity, specificity, and catalytic rates in antibodies and enzymes. As a postdoc with David Baker, Dr. Fleishman developed the first accurate methods for designing protein binders, culminating in the design of broad-specificity influenza inhibitors. The team currently focuses on automated design of repertoires of conventional and camelid antibodies for one-shot isolation of high-affinity, site-targeted binders and inhibitors.

CARL BORREBAECK

Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He founded CREATE Health Translational Cancer Center 2006 and has authored 350 peer-reviewed publications, and is the inventor of over 50 patents. He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the Research!Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. His research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB, SenzaGen AB, and most recently PainDrainer AB.

Carl Borrebaeck

ANDREW BRADBURY

Andrew Bradbury is the Chief Scientific Officer of Specifica, (www.specifica.bio), a start-up founded in 2016 to sell unique client specific antibody libraries. He has worked in the field of phage display and antibody engineering for over 30 years, receiving his Ph.D. at Cambridge University in the MRC under Cesar Milstein, then carrying out research at the CNR Rome and SISSA in Trieste, before moving to the Los Alamos National Lab in 1999, where he became a group leader in 2010.  He left LANL for Specifica in 2017. He was a founder member and the first president (2007-2010) of The Antibody Society, a professional society for all aspects of antibodies. He has published over 140 peer-reviewed articles, including reviews and perspectives on phage display and antibody engineering. His present research interests lie in library construction and selection using next generation sequencing, and he has developed an antibody selection pipeline that combines phage and yeast display in methods that exploit the advantages of each. He maintains an active interest in technology development as it relates to display methods and antibody engineering, and has a long-standing interest in the role auto-antibodies play in the etiology of Celiac disease.

Andrew Bradbury

MICHAEL HUST

Michael studied biology at the Carl von Ossietzky Universität in Oldenburg, Germany, from 1993-1999. He received his PhD from the Leibniz Universität in Hannover, Germany, in 2002. Since end of 2002 he is working as group leader at the Technische Universität Braunschweig, Germany. In 2011, he finished his professorial dissertation (Habilitation) and was appointed as Privatdozent. In 2014 he was appointed as professor for biotechnology.

He published more than 120 articles and filed five patents in the field of antibody engineering and phage display. He co-founded two biotech companies, the mAb-Factory GmbH in 2007 and the YUMAB GmbH in 2012.

KERSTIN MEYER

Kerstin is a Principal Staff Scientist at the Sanger Institute and interested in understanding the regulation of gene expression in health and disease. Kerstin did her undergraduate degree in Biochemistry at Imperial College, London, followed by a PhD in immunology at the MRC Laboratory of Molecular Biology. Since then she has worked at the University of Cambridge studying aspects of gene regulation in immunology and gene regulatory networks in breast and lung cancer. Her appointments have included a Royal Society University Research Fellowship and a Group Leader position at the Department of Oncology. She is currently co-ordinating the Human Cell Atlas efforts at the Sanger Institute.

PETER NILSSON

Peter Nilsson is a Professor in Proteomics at SciLifeLab, KTH - Royal Institute of Technology, in Stockholm, Sweden. He received his PhD degree in Biotechnology from KTH in 1998. Since 2002, he has been the head of the Protein Microarray group within the Human Protein Atlas and the director of the Affinity Proteomics national platform at SciLifeLab since 2013. He is also the Vice Dean of KTH School of Biotechnology.  Peter has been a member of the steering group of HUPO Human Brain Proteome Project (HBPP) since 2015. His research focus is based on the development and utilisation of various antibody, protein, peptide and serum microarray technologies for protein and autoantibody profiling in body fluids and biomarker discovery applications, mainly within neuroscience and inflammation. For publications see publicationslist.com/nipe.

JAMES TRIMMER

Professor Trimmer's research program focuses on the expression, localization and function of neuronal ion channel complexes at the proteomic level, and on generation, validation and use of antibodies in diverse neuroscience research applications. He also directs the UC Davis/NIH NeuroMab Facility that generates high qualicty, low cost monoclonal antibodies for neuroscience research. Validation efforts include diverse assays on brain samples, and transparent reporting of the results, enhancing the utility of NeuroMabs across many areas of neuroscience research. These efforts have resulted in distribution of over 50,000 vials of low cost antibodies, and over 2,000 research publications citing the facility.

JOCHEN SCHWENK

Jochen M. Schwenk is Associate Professor for Translational Proteomics at KTH - Royal Institute of Technology in Stockholm, Sweden. He is the Director of the Biobank Profiling facility at the Science for Life Laboratory and a Principal Investigator within the Human Protein Atlas and the KTH Center for Applied Precision Medicine (KCAP). Jochen is the current chair of HUPO’s Plasma Proteome Project (HPPP) and represents the Antibody Resource Pillar in the executive committee of Human Proteome Project. Jochen’s research focuses on affinity proteomics methods for multiplexed bead-based plasma analysis in large sample sets from population and different disease areas. With the aim to translate discoveries into applications, his team is working on novel affinity-based assays, methods for antibody validation, mass spectrometry, experimental study designs, processing of data and statistical analyses.

JOHN McCAFFERTY

John McCafferty was one of the founders of Cambridge Antibody Technology (now Medimmune, Cambridge) in 1990 and published the first paper/patent describing antibody phage display. Work during this time included the discovery of the antibody which became Humira, the world's biggest selling drug. After 12 years at CAT he returned to academia at the Sanger Institute and the University of Cambridge. In 2012 John formed IONTAS, an innovative biotechnology company using phage display to develop novel antibody therapeutics. In this period John has also developed a novel technology allowing the construction of very large mammalian display libraries permitting the direct discovery of high affinity antibodies with optimal biophysical properties. Finally John has led the development of a novel molecular fusion format wherein naturally occurring, venom-derived cysteine-rich peptides (knottins) are inserted into peripheral CDR loops of an antibody. The resultant bi-specific fusion molecule (KnotBody) retains the folding and function of both knottin and antibody and combines the benefits of each. By this approach IONTAS have already generated ion channel blocking KnotBodies to Nav1.7, Kv1.3 and Asic1a.

DARIO NERI

Dario Neri studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the ETH Zürich, under the supervision of Professor Kurt Wüthrich. After post-doctoral research at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter, he moved to the ETH Zürich in 1996, where he is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences. The research of the Neri group focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders. Other research activities include the chemical proteomic discovery of novel vascular markers of pathology and the development of DNA-encoded chemical libraries. Dario Neri is a co-founder of Philogen (www.philogen.com), a Swiss-Italian biotech company which has brought various antibody products into multicenter clinical trials for the treatment of cancer and of chronic inflammatory conditions. He has published over 350 articles and received the ISOBM Abbott Prize 2000, the Amgen-Dompe’ Biotec Award 2000, the Mangia d’Oro 2001, the Prous Award 2006, the Robert-Wenner-Prize 2007, the SWISS BRIDGE Award 2008, the Prix Mentzer in 2011, the Phoenix Prize 2014 and an ERC Advanced Grant in 2015.

BIRGIT DREIER

Dr. Birgit Dreier has been Senior Scientist in the group of Prof. Dr. A. Plückthun at the Department of Biochemistry, University of Zurich, for more than 10 years and is responsible for the organization, optimization and selection of DARPin (Designed Ankyrin Repeat Proteins) and other scaffold binders and their validation. Here she recently expanded her focus and is leading the High Throughput-Binder Selection Facility (HT-BSF). Prior to this engagement she acquired a strong background in Phage Display using different protein scaffolds (e.g. Fab fragments and zinc finger domains) during her PhD at the Department of Genetics, University of Erlangen, and her postdoctoral training at The Scripps Research Institute, San Diego.

NEBOJSA JANJIC

Nebojsa Janjic has been CSO at SomaLogic since 2009 developing a new generation of aptamers for biomedical applications. Prior to SomaLogic, Dr. Janjic was co-founder and CSO at Replidyne, a company developing new antibiotics, and NeXstar Pharmaceuticals, the original aptamer company. His contributions include the early development of Macugen, the first aptamer and the first VEGF inhibitor approved for the treatment of macular degeneration. Dr. Janjic received a bachelor's degree in molecular biology and a Ph.D. in physical organic chemistry from University of Washington in Seattle and completed postdoctoral training at Scripps Research Institute in La Jolla as Cancer Research Institute Fellow.

SUSANNE GRÄSLUND

Susanne Gräslund did her doctoral training in Biotechnology at the Royal Institute of Technology in Stockholm, Sweden, developing the concepts for what later became the Human Protein Atlas Project. After her dissertation in 2002 she worked for three years at Biovitrum AB in the Target Expression & Purification section. In March 2005, Susanne joined the newly started Structural Genomics Consortium group in Stockholm, heading the Biotechnology team responsible for the generic protein production pipeline. She was then recruited to the SGC Toronto site as Principal Investigator for the Biotechnology team in September 2011 and to manage the SGC efforts to make recombinant antibodies to SGC target proteins. In 2015, SGC established a new lab at Karolinska Institutet in Stockholm, funded by Innovative Medicines Initiative where Dr. Gräslund is having a leading role.

JAN STEYAERT

Jan Steyaert is full professor and Francqui Research Professor at the Vrije Universiteit Brussel (VUB) and Research Director of the VIB-VUB center for Structural Biology. Recently, the Steyaert lab pioneered the use of nanobodies for chaperone-assisted X-ray crystallography (www.steyaertlab.eu), aiming at the highest hanging fruits of structural biology including membrane proteins, amyloidogenic proteins, and now also (transient) multiprotein complexes. The elucidation of the first GPCR structures in the agonist-bound active state demonstrate the power of Nanobodies to stabilize G protein coupled receptor conformational states including transmembrane signalling complexes. Recent work focuses on exploiting the conformational complexity of therapeutic targets for nanobody-enabled drug discovery and on the applications of nanobodies in single particle cryo-EM. He is also co-founder of Ablynx (www.ablynx.com) and Agrosafve (www.agrosafve.com), and founder of ConFo Therapeutics (www.confotherapeutics.com), three successful biotech spin-offs that valorize a unique family of single domain antibodies (nanobodies) derived from camels.

ANN HOLMBERG

Ann Holmberg has worked as Sales Director for Qlucore since 2010, providing easy to use bioinformatic software to help biomedical researchers to be able to easily visualize and analyze their complex protein and gene expression data. After achieving her Master of Science in Biochemistry from the University of Lund, Ann started her career in the biotech industry with development of medi-technical devices and analytical methods based on affinity chromatography. Ann then moved on to a position as Marketing and Sales Manager in the Laboratory Information Management Systems (LIMS) area in 1992, covering the Nordic region for Wilnor and later LabWare Nordic.

LARRY GOLD

Dr. Larry Gold is the Founder, Chairman, and Past CEO of SomaLogic. Prior to SomaLogic, he founded NeXagen, which merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases. Dr. Gold is a professor at the University of Colorado at Boulder, and he was Chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. Dr. Gold is a member of the American Academy of Arts and Sciences, the National Academy of Sciences, and he is a fellow of the National Academy of Inventors.

MARKUS SEEGER

Markus Seeger is Assistant Professor at the Institute of Medical Microbiology at the University of Zurich. Research in his lab is funded by a Swiss National Foundation professorship and an ERC consolidator grant. His group is specialized in generating binders against challenging integral membrane proteins and applies them to investigate transport processes in pathogenic bacteria at the molecular level. He engineered synthetic single domain antibodies (sybodies) to trap membrane transporters in defined conformational states. His group recently invented NestLink, a novel binder generation technology centering on genetically encoded barcoding peptides that allow for binder selections in the absence of a physical genotype-phenotype linkage.

SIMON GOODMAN

Simon Goodman consults on therapeutics and biomarkers targeting cell-adhesion.  He has created and validated many tool and therapeutic antibodies.  As principal scientist at Merck KGaA for 25 years, he was preclinical lead during development of the anti-integrin drugs Cilengitide and Abituzumab - and generated the affinity reagents used in their clinical biomarker studies.  His doctorate was in biochemistry (University of Sussex - 1977).  Work on immunogold reagents for SEM (ICRF - London) was followed by studies on antibodies modulating cell-adhesion (MPI Tübingen - Walter Birchmeier), and on laminin receptors (MPI Martinsried and Erlangen - Klaus von der Mark), where he discovered integrin a7b1. Collaborations with MGH (Amin Arnaout) led to the first integrin X-ray structures.

BJÖRN HOCK

Björn Hock is heading the Biologics Technologies and Development Department at Ferring Pharmaceuticals where he is involved in developing Biologics of different classes for Obstetrics, Gastroenterology and Urology. Before joining Ferring, he worked almost 20 years for Merck KGaA where he held various positions related to Protein- and Antibody engineering and was involved in bringing several molecules into clinical development. Björns research interests in protein and antibody engineering are demonstrated by various peer reviewed publications and patents. Björn got his academic education from the Johann Wolfgang Goethe University in Frankfurt and from the Georg Speyer-Haus in Frankfurt Germany. Björn is a lecturer at the Technical University of Darmstadt where he was appointed as Privatdozent.

DEAN CLIFT

Dean Clift is co-inventor of Trim-Away, a new technology that uses antibodies to target endogenous cellular proteins for degradation. He received his PhD from the University of Edinburgh where he worked on chromosome cohesion in the lab of Adele Marston. He then joined the MRC Laboratory of Molecular Biology in Cambridge as a postdoc in Melina Schuh's lab to work on mammalian female meiosis. Together with Melina Schuh and Leo James, discoverer of the cytosolic antibody receptor TRIM21, he developed the Trim-Away method. He showed that Trim-Away can be used to rapidly degrade endogenous proteins in a wide range of cell types, including primary human cells. Dean is currently a postdoc in Leo James' lab where he is working on novel targeted protein degradation technologies.

THOMAS SCHIRRMANN

Thomas Schirrmann is expert in tumor immunology, immunotherapy and recombinant antibody technologies for more than 20 years. He obtained his PhD in immunology working on chimeric antigen receptor (CAR) gene modified Natural Killer (NK) cells for targeted tumor immunotherapy. In 2005, he became research group leader at the University of Braunschweig. He gained a very broad interdisciplinary expertise in next generation recombinant antibody discovery, engineering and expression technologies, bispecific antibodies, recombinant fusion proteins and CARs as well as gene and immunotherapy. Thomas is author of more than 70 research articles, reviews and scientific book chapters. He is co-inventor of several patents and co-founder of two companies. Since 2012, he is CEO of the award-winning German biotech company YUMAB, which develops fully human antibodies for clients and partners world-wide bridging the gap between research innovation and biopharmaceutical industry (www.yumab.com).

SOPHIE HERNOT

Sophie Hernot obtained her Master of Science in Bio-engineering from the Vrije Universiteit of Brussels. She completed her PhD thesis in Medical Sciences in 2011 on the use of microbubbles (ultrasound contrast agents) as well as Nanobodies for molecular imaging and drug delivery applications. As post-doctoral researcher, and since 2016 as assistant professor in the Laboratory of In vivo Cellular and Molecular Imaging (ICMI, VUB), her research interests are two-fold: 1) design and validation of nanobodies for optical imaging applications, and in particular towards a clinical translation for image-guided surgery, and 2) validation of nanobody-based molecular probes for identification and characterization of high-risk atherosclerotic lesions.

BERND BODENMILLER

Bernd Bodenmiller studied biochemistry at the University of Bayreuth and ETH Zürich and obtained his PhD for his work on system-wide signaling network analysis in the group of Ruedi Aebersold at ETH Zürich. For his postdoctoral training, he joined the laboratory of Garry P. Nolan at Stanford University. There he developed methods for the high throughput analysis of signaling network states by mass cytometry, a technology that allows in principle to quantify 135 proteins and their modifications at the single cell level. In 2012, he became group leader and in 2013 SNF/ERC assistant professor at the University of Zürich. His group develops experimental and computational methods for the comprehensive analysis of tumor ecosystems using highly multiplexed imaging of tissues by mass cytometry. His lab uses these methods to unravel how cells in the tumour microenvironment drive cancer development and ultimately might be exploited for therapeutic targeting.

ULRICH ROTHBAUER

Ulrich Rothbauer is Professor for pharmaceutical Biotechnology at the University of Tuebingen. He received his PhD at Ludwig-Maximilians University (LMU), Munich, in the group of Prof. Walter Neupert revealing the pathomechanism of a mitochondrial disease. In 2006 he became an independent group leader focusing on the development of nanobody-derived tools for protein purification, proteomics and cellular diagnostics. 2008 he founded the Biotech company ChromoTek, which becomes the leading provider of innovative research reagents and technologies based on the nano-/chromobody-technology. His current work is focused on the development of novel chromobodies to visualize endogenous antigens in cellular screening models and on the development of nanobodies as affinity tools for protein analysis and high resolution imaging.

ALEJANDRA SOLACHE

Alejandra joined Abcam in December 2013 and is responsible for managing the output of Abcam’s Global New Product Development and Validation efforts of teams in Cambridge, Hangzhou, Eugene and Branford, CT.  She also plays a key role in developing Abcam’s innovation strategy.  Prior to joining Abcam, Alejandra spent 8 years at EMD-Millipore, where she held various positions, latterly as R&D Director, leading the Antibody and Assay Development teams.  She gained expertise in immunology, cell signalling and epigenetics through postdoctoral fellowships at UCSF and the Trudeau Institute. She was trained as a life science researcher and holds an MS degree in Biochemistry from the Universidad Autonoma de Mexico and a PhD in Immunology from the University College London.

ANITA BANDROWSKI

Anita Bandrowski leads the RRID Initiative, an inter-journal agreement to improve the representation of key biological resources such as antibodies in the scientific literature. The initiative’s goal is to reach every journal in biomedicine, and currently includes over 100 journals from all major publishers, where journal staff actively engage with authors to improve antibody citation practices. Dr. Bandrowski created the antibodyregistry.org in order to address the question of ‘how many antibodies are available to the research community’ and how can they be accounted for and unambiguously cited. The antibodyregistry.org is the authority for antibody identification and it provides RRIDs to authors. Dr. Bandrowski is also co-founder and CEO of SciCrunch, a company that is devoted to creating tools to support journals and author interactions with RRIDs.

ANDREW CHALMERS

Dr Chalmers has a strong interest in improving the reliability of research antibodies. He is a senior lecturer based at the University of Bath and one of the founders and the Chief Scientific Officer of the life science data company CiteAb. CiteAb runs a citation based antibody search engine which helps researchers find antibodies which are suitable for their experiments. He is also a founding guest editor of the F1000Research Antibody Validation Channel that hosts a collection of articles on antibody validation. His research focuses on understanding the behaviour of epithelial cells, with recent work investigating the role of stem cell regulators in prostate cancer.

MIKE TAUSSIG

Mike Taussig, the main organiser of this workshop, is founder and CEO of Cambridge Protein Arrays Ltd. and formerly head of the Protein Technology Group at the Babraham Institute, Cambridge. He codeveloped ribosome display technology for selection of antibodies, and in situ protein arraying, and has collaborated on the production of human antibodies from transgenic mice. He has managed several large EU and ESF networking and research projects, including three EU consortia aiming to establish European resources of affinity binding reagents for analysis of the human proteome, namely ProteomeBinders (2006-2010), AffinityProteome (2009-2012) and AFFINOMICS (2010-2015). He is a board member of the European Federation of Biotechnology and Editor in Chief of the EFB journal New Biotechnology (Elsevier).  Mike is a Fellow of Selwyn College, Cambridge.